Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329 by Malhotra, Binu et al.
ORIGINAL ARTICLE
Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic
squamous cell carcinoma of the head and neck: Southwest Oncology Group
study S0329
Binu Malhotra, MD,1* James Moon, PhD,2 Omar Kucuk, MD,3 Joseph I. Clark, MD,4 Susan G. Urba, MD,1 Gregory T. Wolf, MD,5 Francis P. Worden, MD1
1Department of Hematology Oncology, University of Michigan, Ann Arbor, Michigan, 2Southwest Oncology Group Statistical Center, Seattle, Washington,
3Department of Hematology-Oncology, Emory Winship Cancer Institute, Atlanta, Georgia, 4Loyola University Medical Center, Maywood, Illinois, 5Department of Otolaryngology,
University of Michigan, Ann Arbor, Michigan.
Accepted 18 October 2013
Published online 29 January 2014 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/hed.23522
ABSTRACT: Background. A phase I study and an institutional pilot study
in patients with metastatic/recurrent squamous cell carcinoma of the head
and neck (SCCHN) utilizing biweekly gemcitabine and paclitaxel (GEMTAX),
showed an overall response rate of 53%. 1 This phase II trial was con-
ducted to determine the feasibility, tolerability, and efficacy of this
combination.
Methods. Patients with metastatic/recurrent SCCHN were treated with
gemcitabine (3000 mg/m2) and paclitaxel (150 mg/m2) on days 1 and
15 of every 28-day cycle.
Results. In 57 patients with measurable disease, median progression-
free survival (PFS) was 4 months and median overall survival (OS) was 8
months. Overall response rate of 28% and disease stabilization in 19%
were seen. There were no treatment-related deaths with grade 3/4
hematologic toxicity seen in 20% of the patients.
Conclusion. Biweekly GEMTAX is feasible, well tolerated, and demon-
strated reasonable efficacy. This may be an alternative for patients who
are not candidates for platinum-based chemotherapy. VC 2014 Wiley
Periodicals, Inc. Head Neck 36: 1712–1717, 2014
KEY WORDS: gemcitabine, paclitaxel, recurrent, metastatic,
squamous cell carcinoma of the head and neck
INTRODUCTION
Worldwide, 640,000 new cases of squamous cell carcinoma
of the head and neck (SCCHN) are diagnosed annually,1
the majority presenting with locoregionally advanced dis-
ease. Patients with locally advanced SCCHN are at high
risk for developing local and distant relapses. Those who
develop metastatic disease or recurrent disease, which is
not amenable to salvage surgery or reirradiation, have a
dismal prognosis, and treatment generally consists of pallia-
tion with combination chemotherapy. Cisplatin in combina-
tion with 5-fluorouracil (5-FU) or paclitaxel is considered
the standard of care, achieving response rates from 30% to
40%, with a median survival of 6 to 9 months.2 Addition
of the monoclonal antibody, cetuximab, with platinum and
5-FU prolongs the median survival to 10 months.3 Newer
agents and combination treatments are thus needed to
improve the outcomes in this clinical setting.
Taxanes and gemcitabine are both active in SCCHN and
are known to have different mechanisms of action with
demonstrable single agent activity and non-overlapping
toxicity profiles.4–8 Most of the clinical experience with
paclitaxel4,5 has been with a once every 3-week drug
administration schedule, whereas the majority of clinical
experience with gemcitabine6,8 has been with a schedule
that administers the drug on a weekly basis, 3 of every 4
weeks or 2 of 3 weeks. However, phase I data for an
every-other-week administration schedule has been pub-
lished. In 2 separate studies, the maximum tolerated dose
for gemcitabine was 3000 mg/m29 and 4560 mg/m2,10
respectively. Gemcitabine and paclitaxel (GEMTAX) were
subsequently used in combination in a phase I trial by
Rothenberg et al11 in 37 patients with solid tumors refrac-
tory to conventional therapy. Dose limiting toxicity was
not seen at doses of 150 mg/m2 of paclitaxel and 3000
mg/m2 of gemcitabine biweekly and this dose and sched-
ule of paclitaxel and gemcitabine was recommended for
phase II evaluation.
Based on the data from this phase I study, a pilot study at
Wayne State University utilizing a biweekly GEMTAX
regimen was conducted. This study demonstrated a 53%
objective response rate in patients with advanced or recur-
rent head and neck cancer who had failed prior chemother-
apy.12 Hence, a phase II trial with the same GEMTAX
regimen was then conducted by the Southwest Oncology
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Group (SWOG) in an effort to establish the feasibility, effi-
cacy, and toxicity of this novel regimen in a setting of
patients with recurrent/persistent or metastatic SCCHN.
Here, we report the results of this multi-institutional study.
MATERIALS AND METHODS
Eligibility
Patients with histologically proven SCCHN that was
either metastatic or had persisted or recurred after definitive
surgery and/or radiation therapy or chemoradiation were eli-
gible. Prior chemotherapy for recurrent or metastatic disease
was not permitted. Patients with prior induction or adjuvant
therapy were eligible if at least 6 months had elapsed from
their last course of chemotherapy. Prior treatment with gem-
citabine or taxanes as part of induction, concurrent, or adju-
vant therapy was not allowed and no more than 1 regimen of
induction or adjuvant therapy was permitted. Prior radiation
had to be completed at least 28 days before registration on
this study with resolution of all toxicity from prior therapy.
Patients with both measurable and nonmeasurable disease
were permitted to enroll. All measurable disease had to be
assessed within 28 days before registration, which was
defined by using the Response Evaluation Criteria in Solid
Tumors (RECIST).13 All nonmeasurable disease had to be
assessed within 42 days before registration. Participants
were required to be at least 18 years of age, to have a Zubrod
Performance Status 1 and without any  grade 2 sensory
neuropathy (National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events version 3.0). Patients with
any prior or active central nervous system metastasis, active
infection requiring systemic therapy, or a history of hyper-
sensitivity reaction to products containing polysorbate 80
were excluded. Adequate organ function documented by a
serum creatinine <2 times institutional upper limit of nor-
mal (ULN), bilirubin 2 times institutional ULN, alkaline
phosphatase <2 times institutional ULN or serum glutamic-
pyruvic transaminase <2 times institutional ULN were pre-
requisites for study enrollment. Adequate cell counts as
detailed by a granulocyte count >1500/ml and a platelet
count >100,000/ml were required. Concomitant treatment
with another modality, such as gene therapy, biologic ther-
apy, etc., was not permitted while the patient was on study.
Patients with significant comorbidities that might affect their
ability to tolerate the treatment were excluded. No prior
malignancies were allowed except for adequately treated
basal cell (or squamous cell) carcinoma of the skin, in situ
cervical cancer, or other cancers from which the patient had
been disease-free for 5 years. Pregnant or nursing women
could not participate in this trial and women/men of repro-
ductive potential could participate only if they agreed to use
an effective contraceptive method. The study was approved
by the institutional review boards at each participating insti-
tution, and all patients provided informed consent.
Treatment plan
Gemcitabine (3000 mg/m2) was infused over 30 minutes
on days 1 and 15 every 28 days. Paclitaxel (150 mg/m2)
was infused after gemcitabine over 60 minutes on days 1
and 15 of every 28-day cycle. Every patient receiving
paclitaxel was premedicated with dexamethasone 20 mg
intravenously (IV), diphenhydramine 50 mg, and ranitidine
50 mg IV, 30 to 60 minutes before infusion. Serotonin
antagonist was given IV or PO as clinically indicated.
Each treatment cycle was repeated every 28 days if there
was complete resolution of toxicity.
Treatment evaluations and dose modifications
Before enrollment, patients underwent a history and
physical examination. Pretreatment laboratory studies
included a complete blood cell count with differential and
serum chemistries, including creatinine to monitor the
renal function. National Cancer Institute Common Termi-
nology Criteria for Adverse Events version 3 was used to
classify the adverse effects. Dosage modifications were
done based on the absolute neutrophil count (ANC) and
platelet counts on the day of treatment. If the ANC was
>1500 and platelets >100,000, then the full dose was
administered. If the ANC was 1250 to 1500 and/or plate-
lets were 85,000 to 100,000, the dose was decreased to
2250 mg/m2 of gemcitabine and 112.5 mg/m2 of pacli-
taxel. If the ANC was 1000 to 1249 and/or platelets were
70,000 to 85,000, the dose was decreased further to 1500
mg/m2 of gemcitabine and 75 mg/m2 of paclitaxel. If the
ANC decreased to <1000 or platelets to <70,000, the
dose was withheld. If the cell counts recovered within 1
to 3 weeks to an ANC >1500 and platelets >100,000,
treatment was resumed at the reduced dose of 1500 mg/
m2 of gemcitabine and 75 mg/m2 of paclitaxel; if hema-
tologic recovery took more than 4 weeks, patients were
taken off protocol. For grade 2 neurotoxicity, paclitaxel
dose was reduced to 112.5 mg/m2, and for grade 3 toxic-
ity, patients were removed from protocol.
Response assessment
All measurable lesions up to a maximum of 5 lesions
per organ or 10 lesions representative of all involved
organs were identified as target lesions at baseline. Meas-
urements of the target lesions were used for assessing the
objective response. Response was assessed after every 2
cycles (1 cycle5 28 days). If patients went off treatment
before disease progression, then disease assessments con-
tinued every 8 weeks until progression was documented.
Objective status was recorded at each evaluation and
response was evaluated according to the RECIST criteria.
Patients who achieved a complete response were removed
from treatment after they received 4 additional cycles of
chemotherapy. Otherwise, patients were treated until dis-
ease progression, symptomatic deterioration, or unaccept-
able toxicity. Patients with nonmeasurable disease were
not included in the response assessment.
Statistical considerations
The main purpose of this study was to assess overall
survival (OS) in patients with advanced or recurrent
SCCHN when treated with gemcitabine plus paclitaxel on
a biweekly schedule. The regimen would be considered
unpromising if the true median survival were 6 months.
With 65 patients accrued over 12 months, and an addi-
tional 12 months of follow-up, the power of a 1-sided
0.05 exponential score test would be 0.90. If the observed
median survival was 7.5 months, the regimen was to be
considered for further study.
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Secondary objectives of this study were to assess
progression-free survival (PFS), to assess response in the
subset of patients with measurable disease, and toxicity.
Sixty-five patients were considered sufficient to estimate
the median PFS within 612% (95% confidence interval
[CI]). If 55 patients had measurable disease, the probabil-
ity of response could be estimated within 613% (95%
CI). Sixty-five patients were sufficient to estimate the
probability of any specific adverse event to within 612%
(95% CI). Any adverse event occurring with at least 5%
probability was likely to be seen once (96% chance).
All eligible patients who received at least 1 dose of
the study drug were analyzed for efficacy and toxicity
endpoints. Continuous variables are presented using
median (range). Categorical variables are summarized in
frequency tables. OS and PFS estimates were calculated
using the method of Kaplan–Meier.14 The 95% CI for
the median OS and PFS were constructed using the
Brookmeyer and Crowley method.15 The 95% CI for
point estimates were constructed using the log-log
transformation.
The response rate was defined as the number of
patients with complete or partial responses among the
subset of patients with measurable disease (per RECIST)
at baseline. Exact binomial CIs were calculated for




Sixty-seven patients were accrued between January 1,
2005, and January 1, 2007, from 19 participating institu-
tions. Three patients were ineligible, 2 patients who had
received prior systemic chemotherapy for their recurrent
or newly diagnosed disease, and 1 patient who had newly
diagnosed disease that was not metastatic. In addition, 1
eligible patient did not receive any protocol treatment
because of deteriorating performance status. This patient
was not analyzable for any of the study endpoints. Thus,
63 patients were evaluable. There was an expected male
predominance with a median age of 63 years (range, 40–
82 years). The most commonly involved primary sites
included the oral cavity (32%), oropharynx (21%), and
larynx (25%). At baseline, 57 patients had at least 1
measurable lesion and 6 patients had only nonmeasurable
disease. Among the 63 evaluable patients, 25% of the
patients had a locoregional recurrence/progression, 34%
had a distant metastatic involvement, and 41% had a
combined locoregional and metastatic involvement.
Patient characteristics are detailed below in Tables 1
and 2.
Toxicities
All 63 patients were evaluated for toxicities. There
were no treatment-related deaths. Nine patients (14%)
experienced grade 4 treatment-related adverse events,
which were primarily hematologic, but also included 1
case each of thrombosis/embolism, fatigue, and dyspnea.
Twenty-four additional patients (38%) experienced grade
3 treatment-related adverse events. All grade 3 and 4
adverse events are reported in Tables 3 and 4.
Treatment and tolerance
The median number of cycles administered per patient
was 3 (range, 1–14). Eight patients (13%) received just 1
cycle and 52 patients (83%) received between 2 and 6
cycles. Three patients (5%) received 6 cycles of treatment
and another 15 patients (24%) received 4 or more cycles
of treatment. Twenty-nine patients (46%) required dose
reductions during chemotherapy. Three patients were
taken off the protocol for worsening neuropathy and
another 2 patients discontinued treatment for worsening
performance status despite stable disease in 1 patient and
a partial response in the other.
Response to treatment
The 57 patients who had measurable disease at baseline
were evaluable for response. Complete response was seen
TABLE 1. Patient characteristics.
Characteristic No. of patients (%)
Age













Newly diagnosed 5 (8)
Persistent 7 (11)
Recurrent 50 (79)
Not reported 1 (2)
Primary site*






Paranasal sinuses 3 (5)
Other/unknown 5 (8)
* Human papillomavirus status was not tested.




No prior therapy 8 (12)
Radiation therapy 9 (14)
Surgery 5 (8)
Surgery, radiation therapy 17 (26)
Radiation, concurrent chemotherapy 12 (18)
Surgery, radiation therapy, concurrent chemotherapy 9 (14)
Surgery, radiation therapy, multiagent chemotherapy 1 (2)
Multiagent systemic chemotherapy 1 (2)
Radiation therapy, multiagent systemic therapy 4 (6)
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in 2 patients (3%), 1 of which was unconfirmed. An addi-
tional 14 patients (25%) had a partial response, including 6
confirmed and 8 unconfirmed. The estimated response rate
(confirmed1 unconfirmed complete and partial responses)
was 28% (95% CI, 17% to 42%). A best response of stable
disease was noted in 11 patients (19%); hence, the esti-
mated disease control rate was 47% (95% CI, 34% to
61%). Progressive disease was seen in 21 patients (37%).
The remaining 9 patients could not have their exact
response determined because of inadequate assessments.
PFS and OS, are illustrated in Figures 1 and 2 below.
The estimated median PFS was 4 months (95% CI, 3–6
months). The estimated median OS was 8 months (95%
CI, 7–11 months) and the estimate of 1-year survival was
37% (95% CI, 25% to 48%).
DISCUSSION
In this open label multicenter phase II study, first-line
treatment with the biweekly regimen of GEMTAX in
patients with recurrent or metastatic disease was noted to
be feasible, tolerable, and effective. Median PFS was
noted to be 4 months and median OS was 8 months in
this phase II study. As per the study protocol, an OS of
>7.5 months was considered to be worthy of further eval-
uation. Of the 57 evaluable patients, 16 patients demon-
strated a response and disease stability was seen in
another 11 patients totaling a 47% disease control rate.
The OS seen with this regimen is comparable to the prior
experience with platinum-based combination chemother-
apy regimens that demonstrate OS rates of 6 to 9 months
across studies.2,3 This observation is especially important
as this provides an option for patients who are not candi-
dates for treatment with platinum-based regimens for var-
ious reasons, such as poor renal function, hearing loss, or
hypersensitivity. Even though this study did not assess
refractoriness to platinum compounds before enrollment,
the results of this study do open an avenue for patients
who might be ineligible for or refractory to platinum-
based therapy. Hence, GEMTAX may serve as a reasona-
ble alternative in these select populations.
Although the survival rates are comparable to other
combination regimens, response rates reported in this
study were somewhat lower than expected, 28% versus
30% to 40% reported with most doublets. This may be
because of the refractory nature of the disease being stud-
ied, as most patients had previously treated recurrent
TABLE 3. Hematologic adverse events possibly, probably, or definitely
related to treatment.
No. of patients
Adverse event Grade 4 (%) Grade 3 (%)
Anemia 1 (2) 1 (2)
Leukocytopenia 1 (2) 1 (2)
Neutropenia 4 (6) 3 (5)
Lymphopenia 0 3 (5)
Thrombocytopenia 2 (3) 0
Maximum grade any hematologic
adverse event
6 (10) 6 (10)
TABLE 4. Nonhematologic adverse events possibly, probably, or
definitely related to treatment.
No. of patients
Adverse event Grade 4 (%) Grade 3 (%)
Acne 0 1 (2)
Allergic reaction 0 1 (2)
Anorexia 0 1 (2)
Dehydration 0 1 (2)
Diarrhea 0 2 (3)
Dyspnea 1 (2) 1 (2)
Fatigue 1 (2) 7 (11)
Febrile neutropenia 1 (2) 2 (3)
Hyperglycemia 0 1 (2)
Hyponatremia 0 3 (5)
Hypotension 0 1 (2)
Infection, 0–2 ANC: catheter-related 0 1 (2)
Lung hemorrhage: nose 0 1 (2)
Lung infection, 0–2 ANC: lung 0 1 (2)
Lung infection, 3–4 ANC: lung 0 1 (2)
Memory impairment 0 1 (2)
Mucositis, function: oral cavity 0 1 (2)
Muscle weakness: whole body 0 1 (2)
Musculoskeletal pain: bone 0 1 (2)
Neuropathy-motor 0 1 (2)
Neuropathy-sensory 0 3 (5)
Pain-other 0 1 (2)
Pneumonitis 0 1 (2)
Rash 0 1 (2)
Thrombosis/embolism 1 (2) 0
Vomiting 0 1
Maximum grade any nonhematologic
adverse event
4 (6) 22 (35)
Abbreviations: ANC, absolute neutrophil count.
FIGURE 1. Progression-free survival.
FIGURE 2. Overall survival.
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disease and only 5 patients had a new diagnosis of meta-
static disease without prior therapy. Also, of 57 evaluable
patients, 9 patients with an inadequate assessment of
response were included for intent-to-treat analysis
(accounting toward the denominator — total number “N”)
which may account for the modest response rate.
Seventy-eight percent of the patients in this study had
received prior treatment with radiation therapy and 79%
of the patients had a primary tumor site other than the
oropharynx. In general, chemotherapy does not work as
well in patients who have undergone prior treatment with
radiation. In a study by Argiris et al,16 oral cavity and
hypopharyngeal primary tumors (accounting for over 50%
of the patients studied in our trial) and prior radiation
were noted to be independent unfavorable predictors of
objective response, as was an Eastern Cooperative Oncol-
ogy Group performance status of 1 (vs 0). Sixty-two per-
cent of the patients in this SWOG experience had a
performance status of 1.
Both paclitaxel and gemcitabine are active and well tol-
erated in patients with SCCHN, without any pharmacoki-
netic or pharmacodynamic interactions that may interfere
with the efficacy of these drugs.7 The gemcitabine dose
of 3000 mg/m2 was chosen based on the reported phase I
and II data in a similar patient population12 and was toler-
ated relatively well. The combination of gemcitabine and
paclitaxel in this study was not associated with any
treatment-related deaths. Grade 3 and 4 neutropenia was
seen in only 11% of the patients and thrombocytopenia in
3%, which is much less than the rate of hematologic
toxicity seen with the contemporary platinum-based
regimens2,3,17 and comparable to some of the novel com-
binations being studied.18 Although 29 patients (46%)
required dose reductions, only 5 patients had to stop treat-
ment because of nonhematologic toxicity. Tolerability of
this high dose of gemcitabine was also demonstrated in
another phase II study by Kafri et al,19 in which 76% of
the patients completed treatment without dose reductions.
These findings are also significant as treatment options for
patients with head and neck cancer are often limited by
secondary to multiple comorbidities and declines in per-
formance status from previous therapies. Although GEM-
TAX was used only as front-line therapy in this study, this
combination of gemcitabine and paclitaxel might be a rea-
sonable second-line treatment strategy. Further studies are
needed, however, to prove this hypothesis.
A prior phase I/II study with gemcitabine (800 mg/m2
on days 1 and 8, increased to 1000 mg) with escalating
doses of paclitaxel resulted in an overall response rate of
just 14.8% and median survival of 24 weeks.20 In our
study, we used the same drugs but with a higher dose of
gemcitabine and a dosing interval of every 2 weeks,
which may have accounted for improved efficacy. The
every 2 week dosing interval allowed for complete hema-
tologic recovery and may have facilitated the administra-
tion of high doses without prohibitive cytopenias.
More recently, we have seen an improvement in the
median OS from 7.4 to 10 months when cetuximab was
added to platinum and 5-FU for treatment of patients
with cancers of the head and neck. Although this has
been a landmark breakthrough, this strategy involves use
of a third drug, weekly infusions, and continued mainte-
nance cetuximab in patients with stable disease. This
raises the question of whether maintenance therapy is bet-
ter than sequential second-line therapy, a question that
remains to be answered, and whether the additional cost
of cetuximab is justified.3 Another recent phase II study
by Argiris et al18 evaluating a combination of pemetrexed
and bevacizumab demonstrated a median OS of 11
months, which is very encouraging; however, half the
patients in this study had an oropharyngeal primary, sug-
gesting a large proportion of human papillomavirus
(HPV)-related disease that would have responded well
with many conventional therapies.
Finally, when the responses in our study were evaluated
according to the primary site involved, there was a trend
toward better response in patients with an oropharyngeal
primary. Of the 12 patients with measurable disease, 6
patients had a response (2 documented complete
responses and 4 partial responses), another 3 patients had
stable disease, 2 patients had inadequate assessments, and
1 patient had progressive disease on treatment. This was
not a preplanned subgroup analysis and the number of
patients is small but the findings are concordant with the
published literature if not better, with a disease control
rate of at least 75%.16 HPV status was not available in
our patients, hence, we can only hypothesize that HPV
positivity may have accounted for better outcomes seen
in this subgroup.
In conclusion, this multicenter, phase II study confirms
the feasibility, tolerability, and efficacy of a biweekly
regimen of gemcitabine and paclitaxel. The favorable
results, seen in a recurrent population with mainly nonor-
opharyngeal primary tumors, are relevant, suggesting that
GEMTAX is worthy of further study. Although the
median survival of 8 months seems modest in the current
context of multi-drug combination and directed therapies,
it is definitely comparable to other chemotherapy combi-
nations with respect to survival and responses. There may
be limitations to pursuing a phase III study with this com-
bination, but knowledge of its activity in a population
with poor prognostic risk factors is very pertinent to clini-
cal practice.
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